Explorer les evidences

35,6 %Among the 2016 women of screening age who attended the outreach campaigns, 749 women (35.6%) were screened for cervical cancer.

Kenyacancer du col de l'utéruspublié 2022BMC women's healthPubMeddocument de 7 observations

18,8 %Among HIV-positive patients with cancer, cervical cancer accounted for 18.8% (6 of 32) of malignancies.

Kenyacancer du col de l'utérus · VIH/sidapublié 2023JCO global oncologyPubMeddocument de 8 observations

53,8 %The 3-year disease-free survival was 53.8% among people living with HIV.

Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations

76,5 %76.5% of women previously screened for cervical cancer had one prior screening.

Kenyacancer du col de l'utéruspublié 2025BMC women's healthPubMeddocument de 8 observations

19,7 %In Kenya, 19.7% of new cancer cases among women are attributed to cervical cancer.

Kenyacancer du col de l'utéruspublié 2025Acta cytologicaPubMeddocument de 7 observations

7 %The proportion of HIV-infected women screened for cervical cancer increased from 7% to 9% in the control arm after the intervention.

Kenyacancer du col de l'utéruspublié 2025Asian Pacific journal of cancer prevention : APJCPPubMeddocument de 5 observations

15,7 %Of 632 patients, 15.7% were diagnosed with International Federation of Gynecology and Obstetrics stage IV cervical cancer.

Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718

15,8 %Of 632 patients, 15.8% received cancer-directed therapy with curative potential.

Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718

69,8 %The average relative survival from cervical cancer in the 11 countries was 69.8% at 1 year.

Kenyacancer du col de l'utérusobservé 2005 to 2015publié 2020International journal of cancereurope_pmcdocument de 6 observations

1,73 hazard_rate_ratioIn patients with FIGO stage I-III cervical cancer (n = 190), minor guideline deviations were associated with impaired overall survival (hazard rate ratio, 1.73; 95% confidence interval, 0.36–8.37).

Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718

11 odds_ratioWomen with a history of cervical cancer screening had an odds ratio of 11 for acquiring treatment at follow-up.

Kenyacancer du col de l'utérusobservé 2018publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 7 observations

6 foldWomen living with HIV have a six-fold increased risk of developing cervical cancer compared to women in the general population.

Kenyacancer du col de l'utéruspublié 2025BMC women's healthPubMeddocument de 8 observations

6,4 %Only 6.4% of rural Kenyan women in the survey had ever been screened for cervical cancer.

Kenyacancer du col de l'utéruspublié 2025International journal of environmental research and public healthPubMeddocument de 3 observations

8,01 hazard_ratioParticipants who were diagnosed at late stage of the disease according to the International Federation of Gynecology and Obstetrics staging for cervical cancer (FIGO stage 2B-4B) had more than eight times increased hazard of death compared to those who were diagnosed at early stage (1-2A): Hazard Ratio: 8.01.

Kenyacancer du col de l'utéruspublié 2023BMC cancerPubMeddocument de 12 observations

88 %Squamous cell carcinoma was present in 88.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations

13,4 %Focused training improved community health volunteers' knowledge on cervical cancer to 13.4% in the control arm at end-line.

Kenyacancer du col de l'utéruspublié 2022Journal of cancer education : the official journal of the American Association for Cancer PubMeddocument de 3 observations

33,3 %Close to one third of the participants were unaware of cervical cancer.

Kenyacancer du col de l'utéruspublié 2020PloS onePubMeddocument de 5 observations

In Kenya, cervical cancer is the top cause of cancer deaths and second most prevalent cancer among women aged 15–44.

Kenyacancer du col de l'utéruspublié 2026BMC research notesPubMeddocument de 7 observations

65,8 %Among patients with known stage, 65.8% were diagnosed with Stage III-IV cervical cancer.

Kenyacancer du col de l'utérusobservé 2005 to 2015publié 2020International journal of cancereurope_pmcdocument de 6 observations

74 000 casesHPV vaccination introduction in 2015 rather than 2019 would have averted an additional 74,000 cervical cancer cases.

Kenyacancer du col de l'utérusobservé 2015 vs 2019PubMeddocument de 6 observations

Cervical cancer is the leading cause of cancer death in Kenyan women.

Kenyacancer du col de l'utéruspublié 2023Implementation science : ISeurope_pmcdocument de 5 observationsDOI 10.1186/s13012-023-01322-y

Cervical cancer is the second leading malignancy in incidence among women in sub-Saharan Africa.

Kenyacancer du col de l'utéruspublié 2025BMC women's healthPubMeddocument de 8 observations

2 %From 1st July 2022 to 30th June 2023, 2% of women living with HIV screened had visual inspection with acetic acid (VIA) positive cervical lesions.

Kenyacancer du col de l'utérusobservé 1st July 2022 to 30th June 2023publié 2025BMC women's healthPubMeddocument de 8 observations

225 000 deathsWe estimated 225,000 deaths attributed to cervical cancer over the lifetimes of the 14 evaluated birth cohorts.

Kenyacancer du col de l'utéruspublié 2023VaccinePubMeddocument de 6 observations

1,88 risk_ratioWomen who had spoken about cervical cancer with health workers had 1.88 the adjusted risk ratio for screening in Kenya.

Kenyacancer du col de l'utérusobservé 2022-2023publié 2025BMC public healthPubMeddocument de 8 observations